{"id":17312,"date":"2020-06-04T20:15:39","date_gmt":"2020-06-04T19:15:39","guid":{"rendered":"https:\/\/sclerodermie.ca\/?page_id=17312"},"modified":"2024-09-07T18:39:25","modified_gmt":"2024-09-07T22:39:25","slug":"news","status":"publish","type":"page","link":"https:\/\/sclerodermie.ca\/en\/news\/news\/","title":{"rendered":"News"},"content":{"rendered":"

WINREVAIR\u00ae (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension<\/span><\/h1>\n
KIRKLAND, QC, September 4, 2024<\/strong> \u2013 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that WINREVAIR\u00ae (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.<\/div>\n

Read more<\/span><\/span><\/strong><\/a><\/p>\n

\n

 <\/p>\n

OPSYNVI\u00ae (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)<\/span><\/h1>\n
TORONTO<\/span>, Oct. 15, 2021<\/span><\/strong> \/CNW\/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada approved OPSYNVI\u00ae<\/sup>\u00a0(macitentan 10mg and tadalafil 40mg) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.<\/div>\n
\n
\u00a0<\/div>\n","protected":false},"excerpt":{"rendered":"

WINREVAIR\u00ae (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension KIRKLAND, QC, September 4, 2024 \u2013 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that WINREVAIR\u00ae (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial hypertension (PAH) therapy, for […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":26172,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-actualite.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-17312","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/comments?post=17312"}],"version-history":[{"count":47,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312\/revisions"}],"predecessor-version":[{"id":28496,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/17312\/revisions\/28496"}],"up":[{"embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/pages\/26172"}],"wp:attachment":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/media?parent=17312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Read more<\/span><\/span><\/strong><\/a><\/p>\n